PIMR and Pulmonary Vascular Disease
- Disease/Condition
- Pulmonary Hypertension
- Drug/Device/Intervention
- Pulmonary Index of Microcirculatory Resistance
- Study type
- Observational
- Intervention type
- other
- Primary sponsor
- University of California, Los Angeles
- Location
- Los Angeles, United States of America
- Phase
- N/A
- Start date
- Jan 10, 2023
- End date
- Apr 30, 2024
- Enrollment
- 30 participants
Pulmonary Index of Microcirculatory Resistance (PIMR),Right Ventricle Index of Microcirculatory Resistance (RV-IMR),OCT-derived pulmonary artery wall thickness,OCT-derived thickness-diameter ratio,OCT-derived wall-area ratio
The findings from this innovative, first-in-man, prospective pilot study will elucidate the
 role of PIMR and RV-IMR in pre-capillary PH. The study cohort will consist of patients with
 pulmonary pressures ranging from normal (advanced lung disease patients undergoing lung
 transplant evaluation) to severe PH (PAH and CTEPH patients), and thus will allow for
 identification of a PIMR cutoff. Participants will include: 1) advanced lung disease patients
 undergoing bilateral heart catheterization as part of their pre-lung transplant work-up, and
 2) newly referred patients to PAH and CTEPH clinics undergoing bilateral heart
 catheterization as part of standard of care work-up. All participants will undergo PIMR
 testing, and those with pre-capillary PH will also undergo pulmonary OCT and measurement of
 RV-IMR. The study seeks to define the relationship between PIMR and PH and to establish the
 PIMR threshold that identifies pulmonary microvascular dysfunction as well as to evaluate the
 association of PIMR and pulmonary vascular remodeling on OCT in patients with pre-capillary
 PH. In addition, the study will assess the relationship between RV-IMR and RV pressure
 overload among patients with pre-capillary PH.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT05843461
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT05843461 through Pure Global AI's free database. This phase not specified trial is sponsored by University of California, Los Angeles and is currently Recruiting. The study focuses on Pulmonary Hypertension. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.